153 related articles for article (PubMed ID: 30399318)
1. Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells.
Teng T; Ridgley DM; Tsoy A; Sun GY; Askarova S; Lee JC
ACS Chem Neurosci; 2019 Jan; 10(1):209-215. PubMed ID: 30399318
[TBL] [Abstract][Full Text] [Related]
2. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.
Naito Y; Shimozawa M; Manabe H; Nakabe N; Katada K; Kokura S; Yoshida N; Ichikawa H; Kon T; Yoshikawa T
Eur J Pharmacol; 2006 Sep; 546(1-3):11-8. PubMed ID: 16919261
[TBL] [Abstract][Full Text] [Related]
3. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Matsui T; Yamagishi S; Nakamura K; Kikuchi S; Inoue H
Drugs Exp Clin Res; 2005; 31(5-6):215-9. PubMed ID: 16425978
[TBL] [Abstract][Full Text] [Related]
4. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.
Komoda H; Inoue T; Node K
Clin Exp Hypertens; 2010 Jan; 32(2):121-8. PubMed ID: 20374186
[TBL] [Abstract][Full Text] [Related]
6. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
7. Cytosolic Phospholipase A
Teng T; Dong L; Ridgley DM; Ghura S; Tobin MK; Sun GY; LaDu MJ; Lee JC
Mol Neurobiol; 2019 May; 56(5):3222-3234. PubMed ID: 30112630
[TBL] [Abstract][Full Text] [Related]
8. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.
Manabe S; Okura T; Fukuoka T; Higaki J
Eur J Pharmacol; 2007 Jul; 567(3):252-7. PubMed ID: 17544393
[TBL] [Abstract][Full Text] [Related]
9. Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
Matsui T; Yamagishi S; Nakamura K; Inoue H
J Int Med Res; 2006; 34(6):671-5. PubMed ID: 17295000
[TBL] [Abstract][Full Text] [Related]
10. Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.
Koyama Y; Takeishi Y; Takahashi H; Shishido T; Arimoto T; Niizeki T; Harada M; Suzuki S; Kitahara T; Sasaki T; Kubota I
Cardiovasc Drugs Ther; 2007 Feb; 21(1):69-72. PubMed ID: 17318380
[TBL] [Abstract][Full Text] [Related]
11. Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes.
Tatsumi F; Kaneto H; Hashiramoto M; Tawaramoto K; Obata A; Kimura T; Shimoda M; Hamamoto S; Kanda-Kimura Y; Kamei S; Mune T; Matsuda M; Kaku K
Endocr J; 2015; 62(8):741-7. PubMed ID: 26073866
[TBL] [Abstract][Full Text] [Related]
12. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Konno S; Hirooka Y; Araki S; Koga Y; Kishi T; Sunagawa K
J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
Fan YY; Kohno M; Nakano D; Hitomi H; Nagai Y; Fujisawa Y; Lu XM; Fu H; Du J; Ohmori K; Hosomi N; Kimura S; Kiyomoto H; Nishiyama A
J Hypertens; 2009 Sep; 27(9):1855-62. PubMed ID: 19633569
[TBL] [Abstract][Full Text] [Related]
14. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
Nakano K; Egashira K; Tada H; Kohjimoto Y; Hirouchi Y; Kitajima S; Endo Y; Li XH; Sunagawa K
J Hypertens; 2006 Sep; 24(9):1881-9. PubMed ID: 16915039
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
[TBL] [Abstract][Full Text] [Related]
16. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
17. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
Lukic-Panin V; Kamiya T; Zhang H; Hayashi T; Tsuchiya A; Sehara Y; Deguchi K; Yamashita T; Abe K
Brain Res; 2007 Oct; 1176():143-50. PubMed ID: 17904110
[TBL] [Abstract][Full Text] [Related]
18. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
[TBL] [Abstract][Full Text] [Related]
19. Pin1, endothelial nitric oxide synthase, and amyloid-β form a feedback signaling loop involved in the pathogenesis of Alzheimer's disease, hypertension, and cerebral amyloid angiopathy.
Wang JZ; Zhu WD; Xu ZX; Du WT; Zhang HY; Sun XW; Wang XH
Med Hypotheses; 2014 Feb; 82(2):145-50. PubMed ID: 24332564
[TBL] [Abstract][Full Text] [Related]
20. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
Kurobe H; Matsuoka Y; Hirata Y; Sugasawa N; Maxfield MW; Sata M; Kitagawa T
J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1501-8. PubMed ID: 23535154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
